| Name | Title | Contact Details |
|---|---|---|
Stephen Myers |
Sr. Director, Sr. Counsel - Litigation & Compliance | Profile |
Jeanette Teckman |
Interim Chief Legal Officer | Profile |
Jeanette Teckman |
Chief Legal Officer | Profile |
Lisa Detig |
Vice President and Associate General Counsel - Americas | Profile |
Jared Sine |
Chief Legal Officer and Secretary | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Symbyo Technologies is a Tampa, FL-based company in the Software and Internet sector.
Eyball New York is a New York, NY-based company in the Software and Internet sector.
Awtomic is a subscription eCommerce platform that helps brands build brand loyalty, increase lifetime value, and build sustainable businesses with the power of trustworthy subscriptions.